Short Information | Dyne Therapeutics Inc. (NYSE:DYN)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 17,092 |
Total Actual Volume | 32,929,423 |
Short Trends | |
---|---|
Cover Days | 3 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 855 |
Average Short Percentage | 0.01% |
Is there a DYN Short Squeeze or Breakout about to happen?
See the DYN Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
04-06-2018 | $13.12 | $12.81 | $13.18 | $12.76 | 22,175,203 | 12,074 | 0.05% |
04-05-2018 | $13.42 | $13.14 | $13.66 | $13.05 | 8,887,741 | 3,853 | 0.04% |
04-04-2018 | $13.41 | $13.37 | $13.46 | $13.255 | 1,866,479 | 1,165 | 0.06% |
News, Short Squeeze, Breakout and More Instantly...
2024-06-24 16:00:09 ET Eun Yang from Jefferies issued a price target of $42.00 for DYN on 2024-06-24 12:31:00. The adjusted price target was set to $42.00. At the time of the announcement, DYN was trading at $35.94. The overall price target consensus is at $38.14 with hi...
WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced new preclinical data in a Po...
- Leveraging the FORCE™ Platform, DYNE-302 Achieved Robust and Durable DUX4 Suppression and Functional Benefit in FSHD Preclinical Models - WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focuse...